- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
A retrospective study of the effects of 3,4-diaminopyridine treatment in Lambert-Eaton myasthenic syndrome
-
- Naganuma Ryoji
- Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
-
- Yabe Ichiro
- Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
-
- Takahashi Ikuko
- Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
-
- Matsushima Masaaki
- Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
-
- Kano Takahiro
- Department of Neurology, Hokkaido P.W.F.A.C. Obihiro Kosei General Hospital
-
- Sasaki Hidenao
- Department of Neurology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Bibliographic Information
- Other Title
-
- ランバート・イートン筋無力症症候群における3,4-diaminopyridine治療効果の後方視的検討
Search this article
Description
<p>In this independent clinical study, we analyzed retrospectively the clinical features of 9 cases (6 male and 3 female) of Lambert-Eaton myasthenic syndrome that were administered 3,4-diaminopyridine (3,4-DAP). Four cases showed no cancer and 5 cases had small cell lung carcinoma. Seven cases were positive for anti voltage-gated calcium channel antibodies. Activities of daily living (ADL) were improved by 3,4-DAP in 8 cases that showed mainly weakness of the extremities, but did not improve ADL in 1 case with cerebellar ataxia of paraneoplastic cerebellar degeneration (PCD). Seven cases showed autonomic symptoms, and 6 cases were improved with 3,4-DAP. The maintenance dose varied widely among individuals, with a single dose ranging from 10 to 40 mg. Each patient was prescribed a maintenance dose 3 to 7 times a day. The daily dosage ranged from 36 to 100 mg. Two cases showed adverse effects to the treatment. Of those 2 cases, 1 case treated at 45 mg/day discontinued treatment, but another case treated at 100 mg/day reduced the dosage and continued treatment. The administration period was 1 to 149 months. Three cases have continued 3,4-DAP for more than 10 years. Four cases have discontinued 3,4-DAP, with 2 cases discontinuing due to death, 1 case discontinuing due to progression of cancer, and 1 case discontinuing due to an adverse reaction. Our results suggest that 3,4-DAP treatment is effective for weakness and autonomic symptoms, but may be ineffective for ataxia of PCD. Treatment with 3,4-DAP can be tolerated for a long period, but the optimal dosage varies widely among individuals.</p>
Journal
-
- Rinsho Shinkeigaku
-
Rinsho Shinkeigaku 58 (2), 83-87, 2018
Societas Neurologica Japonica
